N/A N=33 Efficacy of the Recovery Workbook as a Psychoeducational Tool for Facilitating Recovery
Mental Disorders
Primary: Hope Herth Index — 38.93; 35.06 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=160 Supportive Care Intervention In Patients Hospitalized For Hematopoietic Stem Cell Transplantation (Shield)
Complication of Transplant
Primary: Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) Score at Week-2 — 86.60; 94.33 units on a scale
N/A N=90 Tracheal Palpation of Sliding Cuff to Assess Endotracheal Tube Location
Anesthesia Intubation Complication
Primary: Sore Throat — 1.5; 0.6 units on a scale — p=0.04
Phase 2 N=26 Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) for PI3K GNE-positive Participants Registered to S1400B Treated With GDC-0032. — 1; 13; 5; 1 Participants
N/A N=281 A Retrospective Investigation of Local Anesthetic Concentrations in Femoral Nerve Block
Postoperative Pain
Primary: Concentration of Local Anesthetic Injected for Femoral Nerve Block — 117; 81; 83 Participants
N/A N=121 Safety Study of ExAblate for the Treatment of Uterine Fibroids
Uterine Fibroids
Primary: Percent Occurrence of Chronic Leg Pain — 97 percentage of subjects without leg pain
Phase 4 N=9,463 Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus
Primary: Time to First Occurrence of Major Adverse Cardiovascular Events (MACE) During Cardiovascular (CV) Follow-up Time Period — 5.87; 4.57 Events per 100 person years…
Phase 3 N=498 Simplifying the Rabies Pre-exposure Vaccination
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
Phase 1 N=12 A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
Diabetes Mellitus, Type 1
Primary: Part B: Pharmacokinetics: Steady-State Concentrations in Adipose Tissue Interstitial Fluid (ISF) — 11200; 425 picomol per liter (pmol/L)
Phase 2 N=53 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Malignant Mesothelioma
Primary: Progression-free Survival — 3.0; 3.4 months
Phase 2 N=62 A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
Myasthenia Gravis, Generalized
Primary: Improvement in Myasthenia Gravis (MG) Symptoms as Measured by the Mean Change in Quantitative Myasthenia Gravis (QMG) Total Score. — -4.6; -2.7 units on a scale
Phase 3 N=266 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" at Week 16 — 75.56; 52.27; 19.32 percentage of participants…
N/A N=2,124 Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application
Pneumonia
Primary: Clinical Sensitivity and Specificity for Microorganism Detection as Compared to Routine Microbiology and Other Reference Methods Including PCR and Sequencing — 91.4…
Phase 2 N=231 Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — -8.0; -7.5; -9.8 Units on a Scale — p=0.746
Phase 1 N=105 CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
Hypogonadism
Primary: Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism in the CYP19A1 Gene — 3.69; 4.13; 3.82; 0.38 percent change — p=<0.05